DATA REPOSITORY FOR TNIK
ANTI-FIBROTIC PROGRAM
ANTI-FIBROTIC PROGRAM
Figure 1
AI-augmented Pipeline for Target Discovery
Figure 2
Figure 3
Figure 2 data
Figure 2D cell images
Figure 2 WB raw images
Figure 2 RNASeq raw data
Extended Figure 6
A549 TNIK KD; hippo pathway
DOWNLOAD
Architectural superposition of TNIK inhibitor structures
with the predicted INS018_055 binding mode and effects
on TGF-β-induced EMT/FMT cellular programs
with the predicted INS018_055 binding mode and effects
on TGF-β-induced EMT/FMT cellular programs
In vivo effects of INS018_055 treatment in mouse models
of lung diseases
of lung diseases
Figure 3 data
Figure 3C pathology
Figure 4
In vivo effects of INS018_055 treatment by inhalation in rat models of lung fibrosis
Figure 4 data
Figure 4 inhalation study_pathology (HE)
Figure 4 inhalation study_pathology (MT)
Figure 5
In-vitro and in vivo studies on the effect of INS018_055 on kidney cells or mouse model of kidney fibrosis
Figure 5 data
Figure 5A WB raw images
Figure 6
Pharmacokinetic analysis in clinical phase I trials
Figure 6 data
Figure 5B and 5D UUO pathology images
Extended Data Figure 1
Supplementary figure describing Target ID approach
Extended Data Figure 2
PandaOmics scores transparency and in-silico validation of TNIK
Extended Data Figure 3
IPF donor fibroblast and epithelial cell imaging for FMT and EMT assays
Extended Data Figure 4
SPR assays and cell viability assays
Extended Data Figure 3
Extended Data Figure 5
Effect of IN18_055 on TGF-β-induced, or combination of TGF-β and TNF-α induced EMT/FMT cellular programs
Extended Data Figure 5B
Extended Data Figure 5A_raw cell images
Extended Data Figure 5B_WB raw images
Extended Data Figure 6
Effect of TNIK deletion on TGF-β signaling in A549 cells
Extended Data Figure 6D
Extended Data Figure 6B_A549_shTNIK1_Western
raw image
raw image
Extended Data Figure 6A_shTNIK-1
raw images of cells
raw images of cells
Extended Data Figure 7
Extended Data Figure 7_pathology (HE)
Extended Data Figure 7
INS018_055 inhibits inflammation in a bleomycin-induced lung (BLM) fibrosis mouse model
Extended Data Figure 8_pathology
Extended Data Figure 8
Extended Data Figure 8
In vivo study on the effect of combination therapy of INS018_055 and sub-optimal dose Pirfenidone on mouse model of bleomycin induced lung fibrosis
Extended Data Figure 9
In vivo effects of INS018_055 treatment in combination with maximum therapeutic dose of Pirfenidone in mouse models of lung fibrosis
Extended Data Figure 9
Extended Data Figure 10
in vitro and in vivo study of INS018_055 on skin fibrosis
Extended Data Figure 10
Hallmarks of Aging
Assessment
Assessment
Figure 3 INS018_055 concentrations in plasma and lung
Figure 4 INS018_055 concentrations in plasma and lung
Figure 5 INS018_055 concentrations in plasma and kidney
Extended Data Figure 8 INS018_055 and pirfenidone concentrations in plasma and lung